CN112175044A - Polypeptide and method for biologically synthesizing near-infrared silver sulfide quantum dots - Google Patents
Polypeptide and method for biologically synthesizing near-infrared silver sulfide quantum dots Download PDFInfo
- Publication number
- CN112175044A CN112175044A CN201910603088.9A CN201910603088A CN112175044A CN 112175044 A CN112175044 A CN 112175044A CN 201910603088 A CN201910603088 A CN 201910603088A CN 112175044 A CN112175044 A CN 112175044A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- silver
- sulfide quantum
- quantum dots
- infrared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 85
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 85
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 82
- PGWMQVQLSMAHHO-UHFFFAOYSA-N sulfanylidenesilver Chemical class [Ag]=S PGWMQVQLSMAHHO-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 238000000034 method Methods 0.000 title claims abstract description 41
- 230000002194 synthesizing effect Effects 0.000 title description 5
- 238000006243 chemical reaction Methods 0.000 claims abstract description 52
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 38
- 239000002096 quantum dot Substances 0.000 claims abstract description 33
- 229910052946 acanthite Inorganic materials 0.000 claims abstract description 30
- XUARKZBEFFVFRG-UHFFFAOYSA-N silver sulfide Chemical compound [S-2].[Ag+].[Ag+] XUARKZBEFFVFRG-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229940056910 silver sulfide Drugs 0.000 claims abstract description 28
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims abstract description 17
- NKNILFJYKKHBKE-WPRPVWTQSA-N Arg-Gly-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NKNILFJYKKHBKE-WPRPVWTQSA-N 0.000 claims abstract description 9
- PVBBEKPHARMPHX-DCAQKATOSA-N Glu-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCC(O)=O PVBBEKPHARMPHX-DCAQKATOSA-N 0.000 claims abstract description 9
- GJHWILMUOANXTG-WPRPVWTQSA-N Gly-Val-Arg Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GJHWILMUOANXTG-WPRPVWTQSA-N 0.000 claims abstract description 9
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 claims abstract description 9
- 230000003570 biosynthesizing effect Effects 0.000 claims abstract description 9
- 108010050848 glycylleucine Proteins 0.000 claims abstract description 9
- 108010005652 splenotritin Proteins 0.000 claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 5
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical group [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 15
- 229910052709 silver Inorganic materials 0.000 claims description 14
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical group [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 7
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 5
- 125000004434 sulfur atom Chemical group 0.000 claims description 5
- 150000003378 silver Chemical group 0.000 claims description 4
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical group [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 2
- DPLVEEXVKBWGHE-UHFFFAOYSA-N potassium sulfide Chemical compound [S-2].[K+].[K+] DPLVEEXVKBWGHE-UHFFFAOYSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 description 31
- 238000012360 testing method Methods 0.000 description 30
- 230000000052 comparative effect Effects 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 239000007864 aqueous solution Substances 0.000 description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 239000004065 semiconductor Substances 0.000 description 8
- 239000004332 silver Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000012984 biological imaging Methods 0.000 description 4
- 238000002189 fluorescence spectrum Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- -1 silver ions Chemical class 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 238000003775 Density Functional Theory Methods 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000005083 Zinc sulfide Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002173 high-resolution transmission electron microscopy Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002952 polymeric resin Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 229910052979 sodium sulfide Inorganic materials 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 229920003002 synthetic resin Polymers 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 229910052984 zinc sulfide Inorganic materials 0.000 description 3
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 description 2
- 102100026291 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 Human genes 0.000 description 2
- 101710112065 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101100380306 Homo sapiens ASAP1 gene Proteins 0.000 description 2
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 101150003633 PAG2 gene Proteins 0.000 description 2
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 description 2
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 2
- 101000987219 Sus scrofa Pregnancy-associated glycoprotein 1 Proteins 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000731 high angular annular dark-field scanning transmission electron microscopy Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000005424 photoluminescence Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- FSJWWSXPIWGYKC-UHFFFAOYSA-M silver;silver;sulfanide Chemical compound [SH-].[Ag].[Ag+] FSJWWSXPIWGYKC-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000000584 ultraviolet--visible--near infrared spectrum Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DRDVZXDWVBGGMH-UHFFFAOYSA-N zinc;sulfide Chemical compound [S-2].[Zn+2] DRDVZXDWVBGGMH-UHFFFAOYSA-N 0.000 description 2
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000002156 adsorbate Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002173 cutting fluid Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical group 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 238000003333 near-infrared imaging Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000004054 semiconductor nanocrystal Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000005476 size effect Effects 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
- C09K11/58—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing copper, silver or gold
- C09K11/582—Chalcogenides
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/18—Metal complexes
- C09K2211/188—Metal complexes of other metals not provided for in one of the previous groups
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Health & Medical Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Peptides Or Proteins (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
The invention belongs to the technical field of nano biology, and particularly relates to a polypeptide and a method for biosynthesizing near-infrared silver sulfide quantum dots. The polypeptide provided by the invention is used for biosynthesis of near-infrared silver sulfide quantum dots, and at least comprises an amino acid sequence shown in SEQ ID No. 1: glu Gln Leu Gly Val Arg Lys Glu Leu Arg Gly Val are provided. The invention provides a method for biosynthesizing near-infrared silver sulfide quantum dots, which comprises the following steps: providing a polypeptide, a soluble silver salt and a sulfide, wherein the polypeptide at least comprises an amino acid sequence shown in SEQ ID No. 1: glu Gln Leu Gly Val Arg Lys Glu Leu Arg Gly Val, respectively; and (2) carrying out a first reaction on the polypeptide and a soluble silver salt in water, then adjusting the pH value of a reaction solution to be more than 7, adding a sulfide, carrying out a second reaction, and preparing the near-infrared silver sulfide quantum dot. The invention takes the polypeptide at least having the amino acid sequence shown in SEQ ID No.1 as a biological template, quickly and mildly mediates the biosynthesis of the near-infrared silver sulfide quantum dots, and has high specificity.
Description
Technical Field
The invention belongs to the technical field of nano biology, and particularly relates to a polypeptide and a method for biosynthesizing near-infrared silver sulfide quantum dots.
Background
Quantum Dots (QDs), a semiconductor nanocrystal material widely used in the field of electronic science, have been gradually developed and applied to the field of biomedicine in the last two decades due to their unique optical properties, such as high fluorescence intensity, and good stability and size effect, and have become the focus of in vivo and in vitro fluorescent group research. The near infrared II region fluorescence (1000-1700nm, NIR-II) has high tissue penetration depth, low autofluorescence and higher signal-to-noise ratio, and is widely applied to biology.
Silver sulfide (Ag)2S) the quantum dot is a novel quantum dot material capable of emitting near-infrared II-region fluorescence, and is concerned about due to ultralow toxicity, high stability, low cost and good biocompatibility. Ag, like most inorganic semiconductor materials2The S quantum dots are mainly prepared by a chemical and physical synthesis method. However, most inorganic semiconductor materials still need to be synthesized through complicated synthetic routes under severe conditions due to the influence of reaction kinetics, thermodynamics and the like, and the preparation of these materials under mild conditions is still challenging, which becomes one of the main factors limiting the biological applications of these inorganic semiconductors. In recent years, some researchers have proposed the use of engineered peptides from bacterial cell surfaces and phage display libraries as templates for the synthesis of inorganic semiconductor materials, which provides a new strategy for the biosynthesis of inorganic semiconductor materials, and several functional inorganic semiconductor materials such as GaAs nanocrystals, hydroxyapatite, zinc sulfide (ZnS) quantum dots, and silver nanoparticles have also been reported to be successfully prepared. However, biological methods are used to synthesize Ag2S quantumThere are still various problems.
Disclosure of Invention
The invention mainly aims to provide a polypeptide for biosynthesis of near-infrared silver sulfide quantum dots, and aims to provide a biological template with high specificity for biosynthesis of the near-infrared silver sulfide quantum dots.
The invention also aims to provide a method for biosynthesizing the near-infrared silver sulfide quantum dots.
The invention also aims to provide the near-infrared silver sulfide quantum dot synthesized by the method.
In order to achieve the purpose of the invention, the invention provides the following specific technical scheme:
a polypeptide is used for biosynthesis of near-infrared silver sulfide quantum dots, and at least comprises an amino acid sequence shown in SEQ ID No. 1: glu Gln Leu Gly Val Arg Lys Glu Leu Arg Gly Val are provided.
The invention provides a polypeptide, wherein the basic amino acid sequence of the polypeptide is shown as SEQ ID No.1, and the polypeptide with the amino acid sequence has high specificity in the biosynthesis process of near-infrared silver sulfide quantum dots, and can rapidly and mildly mediate the biosynthesis of the near-infrared silver sulfide quantum dots.
Correspondingly, the method for biosynthesizing the near-infrared silver sulfide quantum dots comprises the following steps:
providing a polypeptide, a soluble silver salt and a sulfide, wherein the polypeptide at least comprises an amino acid sequence shown in SEQ ID No. 1: glu Gln Leu Gly Val Arg Lys Glu Leu Arg Gly Val, respectively;
and (2) carrying out a first reaction on the polypeptide and the soluble silver salt in water, then adjusting the pH of a reaction solution to be more than 7, adding the sulfide, and carrying out a second reaction to prepare the near-infrared silver sulfide quantum dot.
Correspondingly, the near-infrared silver sulfide quantum dot synthesized by the method.
The method for biosynthesizing the near-infrared silver sulfide quantum dots takes the polypeptide at least having the amino acid sequence shown in SEQ ID No.1 as a biological template, quickly and mildly mediates the biosynthesis of the near-infrared silver sulfide quantum dots, and has high specificity. The near-infrared silver sulfide quantum dots synthesized by the method have good biocompatibility and high stability, are safe and nontoxic, and can be applied to biological imaging markers and the like.
Drawings
FIG. 1 is a NIR fluorescence emission spectrum of the products of example 1 and comparative examples 1 to 3 of test example 1 according to the invention;
FIG. 2 is a bar graph of NIR fluorescence emission intensity at 1254nm for the products of example 1, comparative examples 4-6 of test example 2 of the present invention;
FIG. 3 is a bar graph of NIR fluorescence emission intensity at 1254nm after incubation of the polypeptide PEP-I with different metal ions and ligands in test example 3 of the present invention;
FIG. 4 is NIR fluorescence emission spectra of the polypeptide PEP-I of test example 4 of the present invention and the products of example 1, examples 4-6 and comparative example 7;
FIG. 5 is a bar graph of NIR fluorescence emission intensity at 1254nm for the products of example 1 and examples 7-9 of test example 5 of the present invention;
FIG. 6 is a bar graph of NIR fluorescence emission intensity at 1254nm for silver sulfide quantum dots in different detergent-containing aqueous solutions in test example 6 of the present invention;
FIG. 7 is an HAADF STEM image of silver sulfide quantum dots made in example 1 of test example 7;
FIG. 8 is a high resolution transmission electron microscopy image (HRTEM) and a Fourier (FFT) transformed image of the silver sulfide quantum dots prepared in example 1 of test example 7;
FIG. 9 is an EDS elemental map of silver sulfide quantum dots made in example 1 of test example 7;
FIG. 10 is an EDX diagram of silver sulfide quantum dots made in example 1 of test example 7;
FIG. 11 shows UV-vis-NIR absorption spectra (left) and NIR fluorescence emission spectra (right) of silver sulfide quantum dots prepared in examples 1-3 of test example 7 in an aqueous environment;
FIG. 12 is a NIR-II fluorescence image of mice obtained 2 minutes after injection in test example 8;
fig. 13 is a schematic structural diagram of a near-infrared silver sulfide quantum dot prepared by a preferred embodiment of the invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
The amounts of the components mentioned in the description of the embodiments of the present invention may not only refer to specific amounts of the components, but also represent proportional relationships among mass, mole and/or volume of the components, and therefore, the amounts of the components in the description of the embodiments of the present invention are within the scope disclosed in the description of the embodiments of the present invention as long as the components are scaled up or down. Specifically, the mass described in the description of the embodiment of the present invention may be a known weight unit such as μ g, mg, g, kg, or the like.
In order to promote the biosynthesis of the silver sulfide quantum dots, the embodiment of the invention provides the following technical scheme:
a polypeptide is used for biosynthesis of near-infrared silver sulfide quantum dots, and at least comprises an amino acid sequence shown in SEQ ID No. 1: glu Gln Leu Gly Val Arg Lys Glu Leu Arg Gly Val are provided.
The basic amino acid sequence of the polypeptide provided by the embodiment of the invention is shown in SEQ ID No.1, and the polypeptide with the amino acid sequence has high specificity in the biosynthesis process of the near-infrared silver sulfide quantum dots, and can rapidly and mildly mediate the biosynthesis of the near-infrared silver sulfide quantum dots.
In a preferred embodiment, the amino acid sequence of the polypeptide for biosynthesis of the near-infrared silver sulfide quantum dots is Glu Gln Leu Gly Val Arg Lys Glu Leu Arg Gly Val. Conventionally, the polypeptide is prepared by combining Fmoc chemistry with solid phase synthesis. In some embodiments, the above method for preparing the polypeptide having the amino acid sequence shown in SEQ ID No.1 comprises the following steps:
a) protecting the N-terminus of valine (Val, V) with an amino protecting group (e.g., Fmoc group), followed by covalent bonding of the C-terminus of valineFormally bound to an insoluble polymeric resin, such as a polymeric resin containing Cl groups; then, sealing unreacted functional groups on the polymer resin; then, washing to remove unreacted amino acid solution; thereafter, the N-terminal amino group (-NH) was exposed by removing the valine protecting group2)；
b) Protecting N end of glycine (Gly, G) by amino protecting group (such as Fmoc group), connecting C end of glycine and N end of valine in the form of amido bond, washing, removing protecting group of glycine to expose N end of glycine;
c) referring to the method of step b), arginine (Arg, R), leucine (Leu, L), glutamic acid (Glu, E), lysine (Lys, K), arginine (R), valine (V), glycine (G), leucine (L), glutamine (Q), and glutamic acid (E) are sequentially attached to the end of glycine;
d) cutting off polypeptide from the high molecular resin, adding the cutting fluid into ether to precipitate the polypeptide, and centrifuging to obtain crude polypeptide; thereafter, the polypeptide is purified using High Performance Liquid Chromatography (HPLC), and the target polypeptide is collected: Glu-Gln-Leu-Gly-Val-Arg-Lys-Glu-Leu-Arg-Gly-Val, labeled as PEP-I, for economy of space, the amino acid sequence can be abbreviated as: E-Q-L-G-V-R-K-E-L-R-G-V.
As another preferred embodiment, in addition to the amino acid sequence shown in SEQ ID No.1, the N terminal and/or the C terminal of the polypeptide for biosynthesis of the near-infrared silver sulfide quantum dot is/are connected with other amino acid sequences or modifying groups. In some embodiments, the polypeptide for biosynthesis of the near-infrared silver sulfide quantum dot is modified with isothiocyanate (FITC) at the N-terminal, labeled as PEP-II, and has the amino acid sequence: FITC-E-Q-L-G-V-R-K-E-L-R-G-V. In other embodiments, the C-terminal linkage of the polypeptide for biosynthesis of the near-infrared silver sulfide quantum dot is modified with cysteine (Cys, C), labeled PEP-III, and has the amino acid sequence: E-Q-L-G-V-R-K-E-L-R-G-V-Cys. In still other embodiments, the polypeptide for biosynthesis of the near-infrared silver sulfide quantum dot is modified with FITC at the N-terminal, and Cys at the C-terminal, and is labeled as: FITC-E-Q-L-G-V-R-K-E-L-R-G-V-C.
In the biosynthesis process of inorganic semiconductor materials, the selection of a proper biological template is a key factor for restricting the successful synthesis of the inorganic semiconductor materials. The polypeptide at least having an amino acid sequence shown in SEQ ID No.1 is selected as a template for biosynthesis of the near-infrared silver sulfide quantum dots, has high affinity to silver ions, and can quickly mediate biosynthesis of the near-infrared silver sulfide quantum dots with high specificity.
We calculated the adsorption energy using spin-limited Density Functional Theory (DFT) calculations in vienna Ab-initio simulation package (VASP) code. Construction of a (2X 2) surface cell with a 15 angstrom vacuum layer for simulating Ag2S to eliminate interactions between adsorbates in the periodic surface. Adsorbing different adsorption end groups of different amino acid molecules on Ag2The adsorption energy was calculated for the same silver atomic site on the S surface and the results are shown in table 1. From the experimental results and DFT, it was found that basic amino acids (arginine, lysine, alanine) are present in Ag2The S quantum dots play an important role in biosynthesis. In some test cases, we found that the polypeptide having the amino acid sequence shown in SEQ ID No.1 has a high specificity in the biosynthesis of silver sulfide quantum dots, compared to other silver binding peptides, which may result from the chemical and structural recognition mechanisms of the polypeptide itself, and may also be affected by other components in the reaction system and/or reaction conditions.
TABLE 1
Correspondingly, the method for biosynthesizing the near-infrared silver sulfide quantum dots comprises the following steps:
s01, providing a polypeptide, a soluble silver salt and a sulfide, wherein the polypeptide at least comprises an amino acid sequence shown in SEQ ID No. 1: glu Gln Leu Gly Val Arg Lys Glu Leu Arg Gly Val, respectively;
s02, carrying out a first reaction on the polypeptide and the soluble silver salt in water, then adjusting the pH of a reaction solution to be more than 7, adding the sulfide, carrying out a second reaction, and preparing the near-infrared silver sulfide quantum dot.
The method for biosynthesizing the near-infrared silver sulfide quantum dots takes the polypeptide at least having the amino acid sequence shown in SEQ ID No.1 as a biological template, quickly and mildly mediates the biosynthesis of the near-infrared silver sulfide quantum dots, and has high specificity. The near-infrared silver sulfide quantum dots synthesized by the method have good biocompatibility and high stability, are safe and nontoxic, and can be applied to biological imaging markers and the like.
Specifically, in step S01, the polypeptide is selected from the above-mentioned polypeptides having at least the amino acid sequence shown in SEQ ID No.1, and has high specific affinity for silver atom, and is used as a biological template for synthesizing the silver sulfide quantum dot. The soluble silver salt refers to a silver salt, preferably silver nitrate, capable of dissociating in water to form silver ions, as one of the main reactants for the biosynthesis of silver sulfide quantum dots. The sulfide is one of main reactants for biologically synthesizing the silver sulfide quantum dots, preferably sodium sulfide or potassium sulfide, and is used for providing sulfur atoms to synthesize the silver sulfide quantum dots.
In step S02, the polypeptide and the soluble silver salt are subjected to a first reaction in water, so that the polypeptide having the amino acid sequence shown in SEQ ID No.1 can complex silver ions of the soluble silver salt in water to form a polypeptide-silver ion complex to mediate synthesis of the near-infrared silver sulfide quantum dots. In the embodiment of the invention, the polypeptide with the amino acid sequence shown in SEQ ID No.1 can highly specifically recognize silver atoms, has high affinity with the silver atoms, and can be assembled with the silver atoms in a coordination bond form to form a complex mixed structure. In the embodiment of the present invention, the first reaction may be performed at normal temperature, or may be performed in a low-temperature or heated environment, and the reaction temperature is preferably 4 to 65 ℃. In some embodiments, the first reaction is accompanied by agitation to facilitate intimate mixing contact between the polypeptide and the soluble silver salt to accelerate the reaction. In other embodiments, in the step of performing the first reaction, the reaction solution is changed from a turbid state to a clear state, and the first reaction is terminated when the reaction solution is clear. In still other embodiments, the first reaction is accompanied by magnetic stirring at a speed of 300-1000 rpm. In still other embodiments, the polypeptide and the soluble silver salt are first separately dissolved in water to produce an aqueous polypeptide solution and an aqueous silver salt solution; then, the aqueous solution of the polypeptide was added to the aqueous solution of the silver salt under vigorous stirring.
In a preferred embodiment, in the step of subjecting the polypeptide and the soluble silver salt to a first reaction in water, the ratio of silver atoms of the polypeptide and the soluble silver salt is 35:1 to 50:1, preferably 36:1 or 50: 1. In some embodiments, the reactive concentration of the polypeptide is 50mg/mL and the reactive concentration of the soluble silver salt is 10 mM.
And adjusting the pH value of the reaction liquid to be more than 7, so that the reaction system is in an alkaline environment to promote the synthesis of the silver sulfide quantum dots. In the embodiment of the invention, in the step of adjusting the pH of the reaction solution to be more than 7, the pH of the reaction solution is adjusted to be 7-12 by using a dilute alkali solution. In some embodiments, the pH value of the aqueous solution of the polypeptide-silver ion complex is adjusted by using low-concentration sodium hydroxide, for example, adding 1mol/L NaOH aqueous solution under vigorous stirring.
In the step of carrying out the second reaction, the sulfide is contacted with the silver of the polypeptide-silver ion complex to react, so as to synthesize the silver sulfide quantum dots. In the embodiment of the invention, in the step of preparing the near-infrared silver sulfide quantum dots, the sulfide is added according to the molar ratio of the sulfur atom of the sulfide to the silver atom of the soluble silver salt of (2-8): 1. In some test cases, the synthesized silver sulfide quantum dots reached the optimal emission intensity when the molar ratio of the sulfur atoms of the sulfide to the silver atoms of the soluble silver salt was 4: 1.
In the embodiment of the invention, the second reaction has mild conditions and low requirements on reaction temperature, and can be carried out at normal temperature or in a low-temperature or heating environment, and the reaction temperature is preferably 4-65 ℃. In some embodiments, the second reaction is accompanied by agitation to promote intimate mixing contact of the polypeptide-silver ion complex with the sulfide to accelerate the reaction. In other embodiments, in the step of performing the second reaction, the reaction solution is dark brown, turbid to clear, and the second reaction is terminated when the reaction solution is clear. In still other embodiments, the second reaction is accompanied by magnetic stirring at a speed of 300-1000 rpm.
To sum up, the method for synthesizing silver sulfide provided by the embodiment of the invention utilizes a biological means to synthesize silver sulfide by polypeptide mediation with an amino acid sequence shown in SEQ ID No.1, has mild conditions and simple operation, can complete the preparation of silver sulfide quantum dots within several minutes, takes short time, and the prepared silver sulfide quantum dots have good luminescence property, high water solubility, good biocompatibility, high stability, safety and non-toxicity, and can be applied to biological imaging markers and the like.
Correspondingly, the near-infrared silver sulfide quantum dot synthesized by the method.
The near-infrared silver sulfide quantum dot synthesized by the method provided by the embodiment of the invention has good biocompatibility and high stability, is safe and nontoxic, and can be applied to biological imaging markers and the like.
In the embodiment of the invention, the near-infrared silver sulfide quantum dots synthesized by the method comprise: the polypeptide and the silver sulfide quantum dot are complexed with a silver atom of the silver sulfide quantum dot through a coordination bond, and the structure of the polypeptide is shown in figure 13. In some embodiments, the particle size of the near-infrared silver sulfide quantum dots synthesized by the above method is 8-12 nm; in other embodiments, in the near-infrared silver sulfide quantum dots synthesized by the above method, silver atoms are used as a core, and sulfur atoms are uniformly distributed on the surface of the silver core.
In order that the details of the above-described implementation and operation of the present invention will be clearly understood by those skilled in the art, and the advanced properties of the polypeptides and the method for the biosynthesis of near-infrared silver sulfide quantum dots of the embodiments of the present invention will be apparent, the implementation of the present invention will be illustrated by the following examples.
Example 1
The zinc sulfide quantum dot is prepared by the embodiment, and the specific process flow is as follows:
1) selecting polypeptide PEP-I, dissolving the PEP-I in an aqueous solution, and preparing a polypeptide aqueous solution with the concentration of 50 mg/mL;
2) weighing silver nitrate, dissolving the silver nitrate in an aqueous solution to prepare a silver salt aqueous solution with the concentration of 10 mmol/L;
3) adding the polypeptide aqueous solution into silver salt aqueous solution with the same volume at room temperature under the condition of vigorous stirring, continuously stirring for reacting for about 2min, stopping the reaction when the reaction solution is clear from turbid, and preparing the polypeptide-silver ion complex;
4) adding 1mol/L sodium hydroxide aqueous solution under the condition of vigorous stirring, and adjusting the pH value of the polypeptide-silver ion compound aqueous solution to 10; then, under the condition of vigorous stirring, adding sodium sulfide according to the molar ratio of the sodium sulfide to the silver nitrate of 4:1, reacting, stopping the reaction when the reaction solution is clear, filtering by adopting a filter membrane of 0.22 mu m, taking the filtrate, and drying to obtain the near-infrared silver sulfide quantum dots.
Examples 2-3 polypeptides different from example 1 were selected to mediate the biosynthesis of silver sulfide quantum dots,
examples 4 to 6 used different Ag/S molar ratios, and examples 7 to 9 used different reaction temperatures in step 3), the details of which are shown in table 2, and are not repeated here for the sake of brevity.
TABLE 2
| Polypeptides | Molar ratio of Ag to S | Reaction temperature in step 3) | |
| Example 2 | PEP-II | - | - |
| Example 3 | PEP-III | - | - |
| Example 4 | - | 1:2 | - |
| Example 5 | - | 1:6 | - |
| Example 6 | - | 1:8 | - |
| Example 7 | - | - | 4℃ |
| Example 8 | - | - | 37℃ |
| Example 9 | - | - | 65℃ |
The specific information of the polypeptides after mutation of part of amino acids in PEP-I is shown in Table 3 in comparative examples 1 to 3, the rest parts are basically the same as those in example 1, and the details are not repeated.
TABLE 3
| Polypeptides | Amino acid sequence | |
| Comparative example 1 | AG3 | A-Y-S-S-G-A-P-P-M-P-P-F |
| Comparative example 2 | AG4 | N-P-S-S-L-F-R-Y-L-P-S-D |
| Comparative example 3 | AG5 | S-L-A-T-Q-P-P-R-T-P-P-V |
| Comparative example 4 | PAG1 | E-Q-L-G-V-R-A-E-L-R-G-V |
| Comparative example 5 | PAG2 | E-Q-L-G-V-K-A-E-L-R-G-V |
| Comparative example 6 | PAG3 | E-Q-L-G-V-R-K-A-A-E-L-R-G-V |
Comparative example 7
This comparative example differs from example 1 in that: the molar ratio of Ag to S is 1: 10; the rest of the process is substantially the same as that of the process of embodiment 1, and the description thereof is omitted here for the sake of brevity.
Test example 1
The final products of example 1 and comparative examples 1-3 were selected as test samples, each test sample was dissolved in water to prepare sample solutions with the same concentration, and then the detection results were shown in fig. 1, only example 1 had an emission peak in the near infrared region, and the emission peak was concentrated in 1254nm, and the detection results of comparative examples 1-3 were substantially coincident with the baseline, indicating that the biosynthesis of silver sulfide quantum dots could not be successfully mediated by the silver binding peptides of comparative examples 1-3, reflecting that the biosynthesis of near infrared silver sulfide quantum dots can be rapidly mediated with high specificity with the amino acid sequence shown in SEQ ID No.1 provided in the examples of the present invention.
Test example 2
The final products of example 1 and comparative examples 4-6 were selected as test samples, each test sample was dissolved in water to prepare sample solutions with the same concentration, and then the detection results were shown in fig. 2, only example 1 emitted strong fluorescence at 1254nm, and comparative examples 4-6 emitted fluorescence at 1254nm with substantially zero fluorescence intensity, which indicates that the biosynthesis of silver sulfide quantum dots could not be successfully mediated by the mutated polypeptides such as PAG1, PAG2 and PAG3, reflecting that the amino acid sequence provided by the example of the present invention and shown in SEQ ID No.1 has high specificity.
Test example 3
Weighing polypeptide PEP-I, dissolving the polypeptide PEP-I in a deionized water solution, and preparing a polypeptide water solution with the concentration of 15 mM; then, the aqueous polypeptide solution is mixed with different metal ions (Ag) at 25 deg.C2+、Au3+、Cd2+、Zn2+、Cu2+And Pb2+) And ligand (SeO)3 2-) Mixing and incubating with metal ions and ligands at a final concentration of 5mM for 5 minutes; then, the detection is carried out by adopting a near infrared fluorescence spectrometer, the detection result is shown in figure 3, and only Ag2+The group emits strong fluorescence at 1254nm, and the fluorescence intensity of other metal ion groups at 1254nm is basically zero, which indicates that the polypeptide PEP-I has high affinity to silver ions and can mediate the biosynthesis of silver nanoparticles with high specificity.
Test example 4
The polypeptide PEP-I and the final products of the examples 1, 4-6 and the comparative example 7 are selected as test samples, the test samples are respectively dissolved in water to prepare sample solutions with the same concentration, then a near infrared fluorescence spectrometer is used for detection, the detection result is shown in figure 4, the polypeptide PEP-I and the comparative example 7 do not emit in the near infrared region, the examples 1 and 4-6 do emit in the near infrared region with different intensities, the near infrared imaging brightness of the example 1 is obviously stronger than that of other groups, and the detection result has high PL brightness characteristics, so that the Ag/S molar size influences the biosynthesis of silver sulfide quantum dots, and the effect is optimal when the Ag/S molar ratio is 1: 4.
Test example 5
The final products of example 1 and examples 7 to 9 were selected as test samples, and each test sample was dissolved in water to prepare sample solutions of the same concentration, and then detected by a near-infrared fluorescence spectrometer, and the detection results are shown in fig. 5, and the emission of example 1 and examples 7 to 9 having different intensities in the near-infrared region, which illustrates that the biosynthesis method of the silver sulfide quantum dots mediated by the polypeptide having the amino acid sequence shown in SEQ ID No.1 in the examples of the present invention is not sensitive to the reaction temperature, and can be performed at normal temperature, or under low temperature or heating environment.
Test example 6
Providing 4 wash solutions comprising: deionized water, a Nonidet P-40 aqueous solution with the weight percentage concentration of 0.5%, a Tween 20 aqueous solution with the weight percentage concentration of 1%, and a Triton X-100 aqueous solution with the weight percentage concentration of 1%;
the silver sulfide quantum dots prepared in example 1 were added to the above-mentioned washing solutions at 25 ℃ to a final concentration of 5mM, incubated for 3 hours, and then detected by a near-infrared fluorescence spectrometer, and the detection results are shown in fig. 6, which shows that the silver sulfide quantum dots prepared in the presence of a high-concentration nonionic detergent have no effect.
Test example 7
The silver sulfide quantum dots prepared in example 1 were taken and observed for physical and optical properties by a transmission electron microscope.
Fig. 7 is an HAADF STEM image of the silver sulfide quantum dots prepared in example 1, and as shown in fig. 7, the silver sulfide quantum dots prepared in the example of the present invention are individually dispersed spherical particles with a particle size of 10 ± 2nm in an aqueous environment.
Fig. 8 is a high-resolution transmission electron microscope image (HRTEM) and an image after fourier transform (FFT) of the silver sulfide quantum dot obtained in example 1, and it is confirmed that the silver sulfide quantum dot obtained by the method of the present invention is a single crystal, and the interlayer distance of the lattice fringes is 0.28nm, which is equivalent to the (-112) plane of the monoclinic silver sulfide quantum dot.
Fig. 9 is an EDS elemental map of the silver sulfide quantum dots prepared in example 1, showing that the silver sulfide quantum dots are mainly composed of two elements, Ag and S, and sulfur is uniformly distributed on the surface of the silver core.
Fig. 10 is an EDX diagram of the silver sulfide quantum dot prepared in example 1, confirming that the silver sulfide quantum dot is mainly composed of two elements of Ag and S.
Fig. 11 shows UV-vis-NIR absorption spectra (left) and NIR fluorescence emission spectra (right) of silver sulfide quantum dots prepared in examples 1-3 in an aqueous environment, with cw excitation at 808nm for measurement of photoluminescence. As shown in the figure, the silver sulfide quantum dots prepared by the embodiments 1 to 3 all show NIR-II emission peaks, which shows that the silver sulfide quantum dots prepared by the method of the embodiments of the invention have high photoluminescence in a near infrared region.
Test example 8
The silver sulfide quantum dots prepared in example 1 are prepared into suspension with the concentration of 2.5nM, 100 muL of the suspension is injected into a mouse body intravenously, then a near infrared fluorescence spectrometer is used for detecting the fluorescence phenomenon, and FIG. 12 is an NIR-II fluorescence image of the mouse obtained after 2 minutes of injection, which shows strong fluorescence and the vascular network of the mouse is clear and visible, and shows that the silver sulfide quantum dots prepared by the method of the embodiment of the invention have the potential of in vivo imaging.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included within the scope of the present invention.
Claims (10)
1. The polypeptide is used for biosynthesis of near-infrared silver sulfide quantum dots, and at least comprises an amino acid sequence shown as SEQ ID No. 1: glu Gln Leu Gly Val Arg Lys Glu Leu Arg Gly Val are provided.
2. A method for biosynthesizing near-infrared silver sulfide quantum dots is characterized by comprising the following steps:
providing a polypeptide, a soluble silver salt and a sulfide, wherein the polypeptide at least comprises an amino acid sequence shown in SEQ ID No. 1: glu Gln Leu Gly Val Arg Lys Glu Leu Arg Gly Val, respectively;
and (2) carrying out a first reaction on the polypeptide and the soluble silver salt in water, then adjusting the pH of a reaction solution to be more than 7, adding the sulfide, and carrying out a second reaction to prepare the near-infrared silver sulfide quantum dot.
3. The method of claim 2, wherein in the step of preparing the near-infrared silver sulfide quantum dots, the sulfide is added in a molar ratio of the sulfur atoms of the sulfide to the silver atoms of the soluble silver salt of (2-8): 1.
4. The method of claim 2, wherein in the step of subjecting the polypeptide and the soluble silver salt to a first reaction in water, the mass ratio of silver atoms of the polypeptide and the soluble silver salt is 35: 1-50: 1.
5. the process according to claim 2, characterized in that the temperature of the first reaction and/or the second reaction is 4-65 ℃.
6. The method according to any one of claims 2 to 5, wherein the soluble silver salt is selected from silver nitrate.
7. A method according to any one of claims 2 to 5, characterized in that the sulphide is selected from sodium sulphide and/or potassium sulphide.
8. The method according to any one of claims 2 to 5, wherein in the step of adjusting the pH of the reaction solution to be higher than 7, the pH of the reaction solution is adjusted to 7 to 12 using a dilute alkali solution.
9. A near infrared silver sulfide quantum dot synthesized by the method of any one of claims 2 to 8.
10. The near-infrared silver sulfide quantum dot of claim 9, comprising: the polypeptide and the silver sulfide quantum dot, wherein the polypeptide is complexed with a silver atom of the silver sulfide quantum dot through a coordination bond.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910603088.9A CN112175044B (en) | 2019-07-05 | 2019-07-05 | Polypeptide and method for biologically synthesizing near-infrared silver sulfide quantum dots |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910603088.9A CN112175044B (en) | 2019-07-05 | 2019-07-05 | Polypeptide and method for biologically synthesizing near-infrared silver sulfide quantum dots |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112175044A true CN112175044A (en) | 2021-01-05 |
| CN112175044B CN112175044B (en) | 2022-09-20 |
Family
ID=73915246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910603088.9A Active CN112175044B (en) | 2019-07-05 | 2019-07-05 | Polypeptide and method for biologically synthesizing near-infrared silver sulfide quantum dots |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112175044B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101034060A (en) * | 2006-03-09 | 2007-09-12 | 同济大学 | Method for quantum dots namo fluorescence probe combined with biochip to find Chinese medicine target |
| CN102826585A (en) * | 2012-09-21 | 2012-12-19 | 南开大学 | Method for producing ultra-small water soluble near-infrared Ag2S quantum dots |
| WO2016024924A1 (en) * | 2014-08-13 | 2016-02-18 | Koç Üni̇versi̇tesi̇ | Near-ir emitting cationic silver chalcogenide quantum dots |
-
2019
- 2019-07-05 CN CN201910603088.9A patent/CN112175044B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101034060A (en) * | 2006-03-09 | 2007-09-12 | 同济大学 | Method for quantum dots namo fluorescence probe combined with biochip to find Chinese medicine target |
| CN102826585A (en) * | 2012-09-21 | 2012-12-19 | 南开大学 | Method for producing ultra-small water soluble near-infrared Ag2S quantum dots |
| WO2016024924A1 (en) * | 2014-08-13 | 2016-02-18 | Koç Üni̇versi̇tesi̇ | Near-ir emitting cationic silver chalcogenide quantum dots |
Non-Patent Citations (3)
| Title |
|---|
| JANAIRO 等: "《Peptide-Mediated Biomineralization》", 30 April 2016, SPRINGER * |
| JAVIDI 等: "Synthesis, Characterization, In Vivo Imaging，Hemolysis, and Toxicity of Hydrophilic Ag2S Near-Infrared Quantum Dots", 《J CLUST SCI》 * |
| 余梦 等: "Ag2S基近红外II区荧光量子点的水相合成优化探究", 《化学学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112175044B (en) | 2022-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fan et al. | Silver nanoclusters encapsulated into metal–organic frameworks with enhanced fluorescence and specific ion accumulation toward the microdot array-based fluorimetric analysis of copper in blood | |
| Kempahanumakkagari et al. | Biomolecule-embedded metal-organic frameworks as an innovative sensing platform | |
| KR100943839B1 (en) | Method for the production of bio-imaging nanoparticles with high yield by early introduction of irregular structure | |
| EP2634135B1 (en) | Synthesis of molecular sieves for modifying the surfaces of nanoparticles having amphoteric ions, and application thereof | |
| Hu et al. | Protein‐and peptide‐directed approaches to fluorescent metal nanoclusters | |
| Wang et al. | Adsorption of phosphorylated chitosan on mineral surfaces | |
| US20090181402A1 (en) | Compositions and methods for coupling a plurality of compounds to a scaffold | |
| Yan et al. | Synthesis of water-soluble Ag 2 Se QDs as a novel resonance Rayleigh scattering sensor for highly sensitive and selective ConA detection | |
| Aires et al. | Boosting the photoluminescent properties of protein-stabilized gold nanoclusters through protein engineering | |
| US11377475B2 (en) | Metal nanocluster scaffolds | |
| Gao et al. | Aprotinin encapsulated gold nanoclusters: a fluorescent bioprobe with dynamic nuclear targeting and selective detection of trypsin and heavy metal | |
| JP2006508095A (en) | Bioactivation of particles | |
| CN112175044B (en) | Polypeptide and method for biologically synthesizing near-infrared silver sulfide quantum dots | |
| US8378075B2 (en) | Covalent attachment of peptides and biological molecules to luminescent semiconductor nanocrystals | |
| Linkov et al. | Selection of the optimal chromatography medium for purification of quantum dots and their bioconjugates | |
| CN113061430A (en) | Synthesis and application of polypeptide gold nanocluster fluorescent probe | |
| Becker et al. | Functional Immobilization of the Small GTPase Rab6A on DNA–Gold Nanoparticles by Using a Site‐Specifically Attached Poly (ethylene glycol) Linker and Thiol Place‐Exchange Reaction | |
| Balu et al. | A multi-responsive intrinsically disordered protein (IDP)-directed green synthesis of fluorescent gold nanoclusters | |
| KR102162923B1 (en) | Nontoxic magnetofluorescent nanoparticles chelating with lanthanide complexes and the method thereof | |
| CN113166072A (en) | Carbene compound, carbene-metal nanoparticle complex and preparation method thereof | |
| Suwatthanarak et al. | Screening and characterisation of CdTe/CdS quantum dot-binding peptides for material surface functionalisation | |
| Ariyasu et al. | Conjugation of Au11 cluster with Cys-rich peptides containing the α-domain of metallothionein | |
| CN113512089B (en) | Polypeptide stabilizer of water-soluble quantum dot and application thereof | |
| KR20230116297A (en) | Composition for detecting food additive zinc oxide, preparation method thereof, detecting and separating method of zinc oxide using the same | |
| JP2006316237A (en) | Nano-cluster that disperses stably in water and has fluorescence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |